Novavax
NVAX
#5817
Rank
โ‚ฌ0.93 B
Marketcap
5,73ย โ‚ฌ
Share price
-1.77%
Change (1 day)
-33.35%
Change (1 year)

Novavax (NVAX) - Total liabilities

Total liabilities on the balance sheet as of September 2025 : โ‚ฌ1.14 Billion

According to Novavax's latest financial reports the company's total liabilities are โ‚ฌ1.14 Billion. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

Novavax - Total liabilities on balance sheet (from 2001 to 2025)

Total liabilities by year

Year Total liabilities Change
2024-12-31โ‚ฌ2.09 B-7.72%
2023-12-31โ‚ฌ2.27 B-15.66%
2022-12-31โ‚ฌ2.69 B4.29%
2021-12-31โ‚ฌ2.58 B232.94%
2020-12-31โ‚ฌ0.77 B142.36%
2019-12-31โ‚ฌ0.32 B-2.48%
2018-12-31โ‚ฌ0.32 B-2.46%
2017-12-31โ‚ฌ0.33 B-11.38%
2016-12-31โ‚ฌ0.38 B345.16%
2015-12-31โ‚ฌ85.39 M123.9%
2014-12-31โ‚ฌ38.13 M65.15%
2013-12-31โ‚ฌ23.09 M38.19%
2012-12-31โ‚ฌ16.71 M70.52%
2011-12-31โ‚ฌ9.8 M-17.47%
2010-12-31โ‚ฌ11.87 M8.68%
2009-12-31โ‚ฌ10.92 M-50.94%
2008-12-31โ‚ฌ22.27 M15.21%
2007-12-31โ‚ฌ19.33 M-8.5%
2006-12-31โ‚ฌ21.12 M-27.94%
2005-12-31โ‚ฌ29.31 M-11.05%
2004-12-31โ‚ฌ32.96 M-13.93%
2003-12-31โ‚ฌ38.29 M-19.01%
2002-12-31โ‚ฌ47.28 M5.4%
2001-12-31โ‚ฌ44.86 M

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
Agenus
AGEN
โ‚ฌ0.44 B-61.49%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
โ‚ฌ1.86 B 62.61%๐Ÿ‡บ๐Ÿ‡ธ USA
Emergent BioSolutions
EBS
โ‚ฌ0.75 B-34.27%๐Ÿ‡บ๐Ÿ‡ธ USA
BioCryst Pharmaceuticals
BCRX
โ‚ฌ0.71 B-37.58%๐Ÿ‡บ๐Ÿ‡ธ USA
AstraZeneca
AZN
โ‚ฌ58.89 B 5,023.97%๐Ÿ‡ฌ๐Ÿ‡ง UK
Pfizer
PFE
โ‚ฌ99.43 B 8,551.69%๐Ÿ‡บ๐Ÿ‡ธ USA
Novartis
NVS
โ‚ฌ53.77 B 4,578.95%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
NanoViricides
NNVC
โ‚ฌ1.12 M-99.90%๐Ÿ‡บ๐Ÿ‡ธ USA
GlaxoSmithKline
GSK
โ‚ฌ52.69 B 4,485.23%๐Ÿ‡ฌ๐Ÿ‡ง UK
Celldex Therapeutics
CLDX
โ‚ฌ43.06 M-96.25%๐Ÿ‡บ๐Ÿ‡ธ USA